Qiagen NV (QGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qiagen NV (QGEN) has a cash flow conversion efficiency ratio of 0.030x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($100.63 Million) by net assets ($3.33 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Qiagen NV market capitalisation for the company's overall valuation and market capitalisation.
Qiagen NV - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Qiagen NV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Qiagen NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qiagen NV ranked by their cash flow conversion efficiency. Explore QGEN cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Voestalpine AG
VI:VOE
|
0.042x |
|
Procore Technologies Inc
NYSE:PCOR
|
0.069x |
|
Madison Square Garden Sports Corp
NYSE:MSGS
|
-0.200x |
|
Smithfield Foods, Inc. Common Stock
NASDAQ:SFD
|
0.037x |
|
DUFRY AG UNSP.ADR/010
F:D2JA
|
N/A |
|
China Merchants Port Group Co Ltd
SHE:001872
|
0.014x |
|
Hainan Airlines Co Ltd A
SHG:600221
|
0.812x |
|
Wuhan Guide Infrared Co Ltd
SHE:002414
|
0.168x |
Annual Cash Flow Conversion Efficiency for Qiagen NV (1995–2025)
The table below shows the annual cash flow conversion efficiency of Qiagen NV from 1995 to 2025. View Qiagen NV share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.78 Billion | $654.33 Million | 0.173x | -8.27% |
| 2024-12-31 | $3.57 Billion | $673.55 Million | 0.189x | +56.48% |
| 2023-12-31 | $3.81 Billion | $459.45 Million | 0.121x | -41.52% |
| 2022-12-31 | $3.47 Billion | $715.26 Million | 0.206x | -0.01% |
| 2021-12-31 | $3.10 Billion | $639.00 Million | 0.206x | +17.28% |
| 2020-12-31 | $2.80 Billion | $492.27 Million | 0.176x | +34.90% |
| 2019-12-31 | $2.54 Billion | $330.84 Million | 0.130x | -4.40% |
| 2018-12-31 | $2.63 Billion | $359.50 Million | 0.136x | +20.89% |
| 2017-12-31 | $2.54 Billion | $286.78 Million | 0.113x | -13.86% |
| 2016-12-31 | $2.61 Billion | $341.60 Million | 0.131x | +5.73% |
| 2015-12-31 | $2.56 Billion | $317.50 Million | 0.124x | +14.39% |
| 2014-12-31 | $2.66 Billion | $287.96 Million | 0.108x | +13.96% |
| 2013-12-31 | $2.72 Billion | $258.96 Million | 0.095x | +5.77% |
| 2012-12-31 | $2.72 Billion | $244.88 Million | 0.090x | -6.08% |
| 2011-12-31 | $2.56 Billion | $244.78 Million | 0.096x | -5.49% |
| 2010-12-31 | $2.48 Billion | $250.75 Million | 0.101x | +6.92% |
| 2009-12-31 | $2.29 Billion | $217.00 Million | 0.095x | -20.41% |
| 2008-12-31 | $1.45 Billion | $173.00 Million | 0.119x | +95.32% |
| 2007-12-31 | $1.39 Billion | $84.81 Million | 0.061x | -66.01% |
| 2006-12-31 | $566.16 Million | $101.48 Million | 0.179x | -11.51% |
| 2005-12-31 | $450.46 Million | $91.24 Million | 0.203x | +50.74% |
| 2004-12-31 | $400.38 Million | $53.80 Million | 0.134x | -29.78% |
| 2003-12-31 | $334.79 Million | $64.06 Million | 0.191x | +37.19% |
| 2002-12-31 | $263.03 Million | $36.69 Million | 0.139x | -48.86% |
| 2001-12-31 | $212.97 Million | $58.09 Million | 0.273x | +15.47% |
| 2000-12-31 | $164.58 Million | $38.87 Million | 0.236x | -16.39% |
| 1999-12-31 | $92.66 Million | $26.18 Million | 0.282x | +78.02% |
| 1998-12-31 | $73.10 Million | $11.60 Million | 0.159x | +0.81% |
| 1997-12-31 | $54.00 Million | $8.50 Million | 0.157x | +83.13% |
| 1996-12-31 | $47.70 Million | $4.10 Million | 0.086x | -73.11% |
| 1995-12-31 | $12.20 Million | $3.90 Million | 0.320x | -- |
About Qiagen NV
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technol… Read more